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remains to be determined ifthese advantages in vitro can be translated 
into reduced risk of development of quinolone resistance in clinical 
use. 
m] Comparative activity of clinaftoxacin against 
Gram-positive and Gram-negative bacteria 
P.C. Appelbaum. Hershey Medical Centeer, Dept.c$Patho/ogy, Hershey, 
PA, USA 
Standardized agar dilution was used to compare the activity of clina- 
floxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, 
piperacillin, piperacillin/tazobactam, trimethoprim-sulfameth- 
oxazole, ceftazidime. and imipenem against 354 Gram-negative non- 
fermenters, Enterobacteriaceae, streptococci and staphylococci. 
Organisms included 143 ciprofloxacin-susceptible strains (MIC 
< = 1 .0 mg/L) and 21 1 strains with raised ciprofloxacin MICs 
(=2.0 mg/L). Clinafloxacin yielded the lowest MICs of all quino- 
lones tested, with MICs < =0.5 mg/L against ciprofloxacin- 
susceptible and MICd < = 16.00 mg/L against ciprofloxacin-inter- 
mediate and -resistant Gram-positive and -negative organisms. By 
comparison, MICs of levofloxacin, trovafloxacin and sparfloxacin 
were < =2.0 mg/L against ciprofloxacin-susceptible strains, with 
many ciprofloxacin-resistant organisms yielding MICs of 32 mg/L for 
all three quinolones. Among ciprofloxacin-resistant strains, clina- 
floxacin, levofloxacin, spariloxacin and trovafloxacin were generally 
most active against Stenotrophomonas maltophilia (MICs< =4.0 mg/L) 
and Srreptucuccm pneumoniue (MICs < =2.0 mg/L). Ceitazidme, 
piperacillin + tazobactam and trimethoprimsulfamethoxazole yielded 
higher MICs against ciprofloxacin-resistant compared to ciprofloxacin- 
susceptible Gram-negative non-fermenters. Enterobacteriaceae and 
Enterorocrusfaecium also yielded high MICs against these compounds. 
Imipenem resistance was only seen in Gram-negative non- 
fermenters, methicillin-resistant Staphylococcus uureus and enterococci. 
Clinafloxacin shows promise for treatment of infections caused by 
ciprofloxacin-resistant organisms. 
Time-kill tests were used to test possible synergy between 
clinafloxacin and a variety of other agents against 44 Gram-negative 
and -positive bacteria, most with clinafloxacin MICs being 1 mg/L. 
When synergy was considered at 6 h, 12 h, and 24 h, clinafloxacin 
was synergistic with ceftazidime, amikacin and imipenem against: 
2/3, 2/3, 3/3 Pseudomonas aeruginosa; 3/3, 013, 1/3 Stenotrophomonas 
maltophilia; 2/3, 3/3, 3/3 Acinetobacter spp; 3/3, 2/3, 3/3 Burkholderia 
cepaciu; 0/3, 2/3, 1/3 Escherickiu coli; 1/3, 1/3, 1/3 Klebsiella 
pneumuniae; 1/3, 113,013 Enterobactercloacae; 3/3,3/3,3/3 Citrobacter 
jeundii; 3/3, 3/3, 2/2 Serratia marcescens; 2/2, 212, 2/2 Dtovidencia 
stuartii; 1/1, 0/1, 011 Morganella murganii. Among Gram-positive 
bacteria, clinafloxacin showed synergy with vancomycin, teicoplanin, 
cefotaxime and vancomycin in: 2/3, 3/3, 3/3, 2/2 methicillin- 
resistant Staphylococcus nureus; 1 /3, 1/3, 113, 0/3 Enterococcus/aecalis; 
1/3, 1/3, 1/3, 1/3 Enterocuccusfaecium (the only strain with a low 
clinafloxacin MIC of 0.25 mg/L). Against pneumococci, clina- 
floxacin showed synergy with vancomycin, penicillin G, cefotaxime 
and synercid in 013, 2 / 3 ,  213, and 0/3 strains. In all cases of synergy, 
clinafloxacin MICs were lower than those obtained with the drug 
alone, and, in most cases, subinhibitory levels of the accompanying 
drug were also found. 
Is113) Surgical infections: clinical options for 
diagnosis and treatment 
C.E. Nord. University Hospital, Dept. of Immunolofl, Huddinge, 
Sweden 
Intra-abdominal infections are a common and serious clinical 
problem, particularly in general surgery and surgical intensive care 
units. These infections are nearly always polymicrobial in nature, 
involving both aerobic and anaerobic pathogens. Treatment usually 
includes drainage, intensive care and administration of broad- 
spectrum antimicrobial agents. Computerized tomography is an 
important tool for evaluating patients suspected of having an intra- 
abdominal infection, and for guided aspiration of suspected intra- 
abdominal abscesses. Antimicrobial agents must penetrate to the 
infection site in concentrations sufficient to overcome the effects of 
a number of factors that may lower the drug’s activity, including high 
bacterial density, metabolic inactivity and slow growth rate of the 
bacterial inoculum, low pH, very low oxygen tension, and necrotic 
tissue. Quinolones are potent broad-spectrum antimicrobials with 
rapid bactericidal activity that have been used successfully in the 
treatment of a variety of infections. Older quinolones such as cipro- 
floxacin possess excellent activity against Gram-negative bacteria, 
good activity against Gram-positive bacteria, and poor activity against 
anaerobes. Ciprofloxacin in combination with an anti-anaerobic 
agent has shown good efficacy in the treatment of intra-abdominal 
infection. The availability of newer quinolones with enhanced 
activity against anaerobes as well as Gram-positive bacteria makes 
treatment of intra-abdominal infections a possibility. Of these newer 
agents, clinafloxacin has been shown to be active against many 
pathogens that are commonly isolated from patients with intra- 
abdominal infections, including quinolone-resistant bacteria. Clinical 
data with this agent are encouraging, and the results from ongoing 
intra-abdominal infection trials are awaited with interest. 
Exotoxi ns 
Toxins with intracellular actions 
K. Aktories. Uniuersitiit Freiburg, Pharmakolog. Institut, Freiburg, 
Germany 
At least four distinct steps are involved in the effects of bacterial 
protein toxins acting inside eukaryotic target cells, including: (1) 
binding of the toxin to the target cell membrane, (2) internalization 
of the bound toxin, (3) translocation into the cytosol, and (4) 
modification of the intracellular target. Studies fkom recent years have 
greatly increased our knowledge of these processes. Most remarkable 
has been the progress in respect to structure-function analysis of the 
toxins, identification of novel eukaryotic toxin substrates and the 
understanding of the molecular mechanisms by which toxins mohfy 
their eukaryotic targets. These advances have depended on successful 
crystal structure analyses of toxins and the application of cell- 
biological methods, inaugurating a novel field of a cellular micro- 
biology. Recent advances in the understanding of toxins acting on 
the cytoskeleton will be discussed in detail. 
A b s t r a c t s  25 
I s115 I Shiga toxin and shiga-like toxins: the 
molecules and their action on cells 
K.  Saiidvig', M.  1. Torgersen', G. Skretting', 0. Garred', 
A. Polesskaya', S. Olsnes', J. Kozlov', B. van Deurs". 
J i r  21folcctilnr Biolcy~~, Acadetity of Siietiirs, Mosc~i iy  Rimin; -'The Pariirrn 
Ziistiiirrc, t ' i i i t w s i f y  Cop~~iilzqcw, Drtiiiinrk 
Shiga t ~ x u i  md the related Shiga-like toxins bind to glycolipids at 
the cell surface via five small I3 subunits. The enzymatically active A 
fragment, ~ l i i c h  is noncovaleiitly associated with the binding moiety, 
consists of an A I  and ail A2 doiiiain, connected by 3 furin-sensitive 
sequrncc i n  '1 loop created by a disulfide bond. During intoxication 
of cells this sequence is cleaved. Recent data demonstrate that aiiiino 
acids surroundiiig the fiirin recognition sequence are essential for 
rcco~rution by the enzyine. Shiga toxin has previously been seen to 
enter clatlirin-coated areas at the cell surface before i t  IS endocytosed, 
transported to the Golgi apparatus and in toxin-sensitive cells also 
trm\ported to the endoplasmic reticuluni (ER) before translocation 
to the cytosol. Functional clathrin i\ clearly required for intoxicatiou 
of cells. Cells that synthesize antisense clathrin in an inducible 
manner d o  becoine resistant to the toxin. Also, the cholesterol con- 
tent of the nicriibrane is important for the intoxication. Reduction 
of iiieiiibl.ane cholesterol by treatment with cyclodextrin protects 
celk ;igwist the toxin. I t  has previou\ly been shown that the lipid 
c t ) m p o s i t i ~ ~  of the toxin receptor is important for intracellular 
routing of the toxin and for the toxic action. Productive receptors for 
Shiga toxin \re111 to be less stable than the majority of the binding 
sites, suggesting a correlation between the ability to transport toxin 
to the Golgi and the E R  and their rate of degradation. Thus, sorting 
from cndosoines to later cellular compartments is clearly a critical step 
in  intoxication. 
niqiari Rndirini Hospital, Oslo, Nontuy; 'Gi,qelhardt Ziisrittctr 
Recent acquisitions on the mode of action of 
H. pylori toxins VacA and Hp-NAP and of the 
lethal factor of B. anthracis 
C. Montrcucco. Ti~~~vcvsity $Padova, Depr. of Biorncd. i C crenics, ' 
Padodon, Iraly 
We aim 'it understanding the mechani\iii of action of toxins involved 
in the pathogenesis of severe gastroduodeual pathologies and of 
anthrax to define the molecular and cellular pathogenesis of the 
and to devise new therapeutic treatiiients. We concentrated 
on  the vacuolating cytotoxin (VacA) and on the neutrophil-activating 
protein (NAP) and 011 their effrcts on  sparse celk in culture, polarized 
epithelial nioiiolayers and neutrophils, as well as the lethal factor (LF). 
On spxsc  cell\ in culture. VacA causes extensive vacuolization, and 
intoxicated cells are defective in degradation of external ligands such 
'IS EGF and 111 processing of cathepsin precursors. Acidic hydrolases 
are secreted in the iiirdiuin following VacA intoxication, and this 
phenomenon may be relevant to the damage to the stomach iiiucosa, 
because they are pxticularly active in this environnieiit. VacA also 
inhibits :uitigen processing and presentation and this effect may well 
contribute to Hdiiobai-tcv pylari growth via depression of the host 
immune response. VacA also causes '1 specific lowering of ti-an\- 
epithelial inonolayer resirtauce with increased paracellular per- 
meability of inetabolitrs and ions supporting bacterial growth on the 
apical surface. 
XAf' itidicier tltf prod~~c/io~i qf nvmiur O X ) ~ W  radzials uin iirdiicrioii of 
tltr osscnibly qf f l i p  NADPH oxidasc incdiared by iitircasr of t l i e  cyrosolir 
talciirrin ioiiirntvatiow. 
LF was demonstrated to be a metalloprotease acting 111 the cell 
cytotosol specitic'illy on several MAP-kinase isoforins which are 
cleaved within a few amino acid residues from the N-tcriiiitiiis. 
Further studies are needed to link this biochemical activity t o  
n i ~ r o p h a g e  death. 
Staphylococcal alpha-toxin, archetype of a 
pore-forming cytolysin 
S. Bhakdi. Z/istitittr qf Mediial A4iin)l1i1~loy~~ mid  Hlyieiit: (iriitwsity o/ 
M n i m ,  ,Miiiiz, G w ~ a i t y  
Advances in  the field of staphylococcal alpha-toxin, the bc\t studied 
prototype of an oligomerizing, pore-forming cytolysin, will bc 
summarized. Alpha-toxin binds as a nioiioiiier to high-affinity \ite\ 
on susceptible cells, and then oligomerizes to form cylinder-chaped 
oligoniers, with a hydrophilic chxinel approximately 1 n i i i  i n  
diameter running through their center. Toxin oligoiners form \poii- 
taneously in  the presence of detergents such a? deoxycholnte, m d  
these aggregates have been crystallized and the three-dimensio~ial 
structure solved. Iktergent-induced oligoniers :\re heptamerc, dnd 
the walls of the pores are formed by seven aiiiyhipathic a m i n o  acid 
sequences from raidues 11 8-1 40 emanating from each proiiioter. 
The membrane-inserting domain of alpha-toxin has, i n  parcillrl, been 
mapped with the use of cysteine substitution iiiutaiit\ carrying thc 
environmentally sensitive fluoi-escent probe acrylodaii. Thc\c \tiidies 
have provided direct evidence that residue\ 11 8-1 40 enter the lipid 
bilayer to form the transnieinbrane pore. Cells attacked by a1ph.i- 
toxin react in response to uncontrolled ion fluxes. Pot~issiuni e f h x  
trigger\ unpredictable proc , including caspase-dependeiit 
reactions such as IL-/3 maturation and apoptori\. Ca' influx provokes 
secretion, production of eicosanoids and NO, and cytoskeletd 
dysfunction. Certain cells can resist attack by alpha-toxin, by ,111 
unknown niechanism that prevents insertion of the porc-fimning 
sequence. Other cells can close the siiiall poim produced by this 
toxin, apparently by a membrane-remodeling niechariisiii. h e -  
forming toxins emerge as multi-faceted microbial etFector nioleculcs 
that can provoke a plethora of biological effect? further t o  a n d  
independent of their direct cytocrdal action. 
Novel immunologic aspects of bacterial toxins 
T. Hirst. liriiimsity qf B r i d ,  Brisfol, UK 
Recent advances in the study of cholera toxin a i d  rclatcd E. ioli 
entcrotoxins have revealed that they can profoundly modu1.1te the 
immune system. The  binding of the noii-toxic B-subunit cotnponcnt 
ofthese toxins to GM1 ganglioside-a glycolipid found in the p l m n ~ i  
nienibranes of eukaryotic cells-has been fi)und to alter the nature 
of ininiune responses to coadniinistered antigens by modulating the 
activation and antigen-presenting properties of niacrophagr5, l3-cells 
and deiidritic cells, altering the differentiation of T-helper cells, 
inducing apoptosis of C138 T-cells and changing the profile of 
cytokine induction. All of these events orchestrate a downreplation 
of pro-inflammatory itnniutie responses-a finding that ha? led to thr 
development and testing of the B-subunit 
prevention of inflammatory auto~mmuiie disorders such a\ arthritis, 
diabetes and multiple sclerosis. The  13-subunits have n l w  been 
denionstrated to boost secretory IgA response\ to vaccinc antigen- 
thus opening the prospect of using them as adjuvants in  pi-ogr.1nx of 
niucosal vaccinatioii against iiifectious diwases. 
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Epidemiology and current clinical challenge of 
tuberculosis 
T. Schaberg. Clzesf Clink Ihircrctedt, Deacowrss Hospital, Rotenbutg, 
Germany 
The world is currently facing a widespread tuberculosis epidemic. 
According to the World Health Organization, more than 1.8 billion 
people are infected with Mycobacterium tuberculosic worldwide. The 
current prevalence of active tuberculosis is more than 22 million, and 
each year at least 8 million new cases will occur as well as 3 million 
deaths. Therefore, between 1990 and 2000, more than 30 million 
people will die from tuberculosis-more than ever before within a 
decade. More than 90%) of all new cases and deaths occur in 
developing countries, which are struggling under the enormous 
economic burden induced by this single disease. Most cases can be 
observed in Sub-Saharan Africa and South-East Asia. In both these 
regions, infection with HIV is also endemic, resulting in a 14% 
infection rate in all TB cases. Moreover, tuberculosis is still the main 
cause of death in HIV-positive people. To make things worse, we are 
observing a growing number of resistant M .  tirbercirlosis strains 
worldwide (e.g. 6.6% single drug resistance in previously untreated 
patients and 13% multidrug resistance in patients with a history of 
previous antituberculous therapy). Therefore, the main challenges for 
the coming years are the implementation of sufficient TB-control 
programs worldwide and the battle against resistance. However, 
without strong financial support froin the developed countries, we 
will not achieve this goal. 
Mycobacterial diseases 
(s1211 Genetics of drug resistance in mycobacteria 
A. Telenti. Dioisioii of hfertioirs Diseases, Centre Hospiralier 
Unioersitaire kudois ,  Lausaizm, Switzerland 
While the global niagnitude of the muitidrug-resistant tuberculosis 
(MDR-TB) problem is not well known, gaining imight into the 
mechanisms of resistance and into the pathogenicity and trans- 
niissibility of MDK-TB will be important for future control of the 
disease. Mutations in the katC, i d i A ,  ahpC and kasA genes are found 
in 75-90% of isoniazid-resistant strains, and rifampin resistance is 
associated with rpoB inutatioris (95%). Genetic information is also 
available for pyrazinaniide (pncA, .fasi), ethambutol (embB), strepto- 
mycin (16s rDNA and rpsL), clarithromycin (23s rDNA), 
aniikacin-kananiycin (16s rDNA), and the fluoroquiiiolones (WrA, 
g y ~ B ,  &A). At a practical level, these data allow the development of 
novel resistance testing methodologies, and may permit better design 
of MDR-TB treatnient strategies. Mutation analysis may assist in the 
assessment of the pathogenicity of MDR-TB strains. In the future, 
knowledge of the molecular mechanisms of action of antituberculous 
drugs, the availability of the complete tuberculosis genome sequence, 
together with protein structural information and conibinatorial 
chemistry, may lead to new drugs. 
Vaccination strategies for tuberculosis 
S.H.E. Kauhann. Max Planck Insfitut, D e p .  of Iniiniirrolo‘qx B c r h ,  
Ccrinany 
Tuberculosis constitutes a major global health threat. Although UCG 
represents a vaccine capable of conferring protection against child- 
hood tuberculosis, it fails to provide sufficient protection against the 
most prevalent form of the disease, adult pulmonary tuberculosis. 
Thus, novel vaccination strategies against tuberculosis are urgently 
required. Tuberculosis is a chronic infectious disease caused by Myco- 
bacteriim tirberiulosis, which is capable of persisting in macrophages. 
Acquired resistance depends on multiple T-cell populations, com- 
prising not only CD4 T-cells but also CD8 T-cells and uncon- 
ventional T-cells. Activation of niycobactericidal mechanisms in 
macrophages by interferon-gainma and other cytokines from T-cells 
is crucial for controlling the pathogen. In addition, other T-cell 
functions are required for optimal protection. Thus, any future 
vaccine has to mobilize the most appropriate combination of T-cells 
needed for control of M .  tubercirlosis in the host. From an inimuno- 
logic standpoint, BCG may fail to induce the appropriate com- 
bination of T-cells and/or lack protective antigens. Vaccine strategies 
currently pursued include: secreted antigens in adjuvant; naked 
DNA; recombinant bacterial or  viral vaccine carriers expressing 
specific antigem of M. fr~bcrruiosis; M.  ruberrdosis deletion mutants; 
iiiiproved recombinant BCG capable of stimulating the appropriate 
T-cell combination and expressing unique antigens of M.  tuberculosis. 
The potential advantages and disadvantages of these different vaccine 
candidates will be discussed. 
I S123 I Progress in antimycobacterial treatment 
J.E Murray. Urtivcrsity .f Calijirrria, Sun Franrisio, CA, CJSA; 
lizternutiotiai Ur8ion Agu imf  Ebrrculosis and Lun‘q Diseuse, Paris, France 
The five standard ‘first-line’ antimycobacterial agents used for the 
treatment and prevention of Myrobncterium tu6erculosis disease were 
developed well over a quarter ofa  century ago: streptomycin (1944), 
isoniazid (1952), pyrazinaniide (1952), ethambutol (1961), atid 
rifampicin (1966). Since then, the development of truly novel 
compounds that would significantly add to the available therapeutic 
armamentariuni has been disappointingly slow, especially in view of 
the well-publicized outbreaks of multidrug-resistant tuberculosis 
(MDR-TB) and the identification by WHOAUATLD of numerous 
‘hot-spots’, regions of the world where there is an alarmingly high 
prevalence of MDR-TB. Current new drugs of interest are the 
following. 
Fluoroquinolones. Several fluoroquinolones, which have become 
the most important ‘second-line’ antituberculosis drugs, are available, 
although thorough clinical comparisons are scarce. Because of its 
apparent safety and good activity, levofloxacin may be the agent of 
choice. Sparfloxacin is also effective against A4. tubercirlosis, but photo- 
toxicity is a problem in 10% of recipients (may be lower in dark- 
skinned persons). Because of its anti-M. ruberrrrlosis activity, moxi- 
floxacin is 3n interesting new compound. 
Macrolides. N o  macrolide antibiotics with significant in vitio 
activity against M .  tubmulosis have been identified. In contrast, 
clarithroniycin has been shown to be effective in the treatment of 
disseminated Myiobactrriuni aoium complex (MAC) disease, and both 
clarithromycin and azithroniycin have been approved in the USA for 
prophylaxis against MAC. 
Rifaniycin derivatives. Rifabutin is approved in the USA for 
prophylaxis against MAC and is used in several countries for the 
treatment of tuberculosis. It has substantial cross-resktance with 
rifampicin, but because of relatively little bidirectional drug inter- 
action with indinavir, the CDC has recoinmended that rifabntin be 
used in place of rifampicin in the treatment of HIV-infected tuber- 
culosis patients for whom an HIV protease inhibitor is indicated. 
Rifapentine is of considerable interest because of its long half-life and 
the possibility of once-weekly dosing; a phate 111 trial is now under- 
way and experimental studies suggest that the combination of rifa- 
